JP2013054023A - Git1遺伝子欠損マウス及びこれを用いた薬物スクリーニング方法 - Google Patents
Git1遺伝子欠損マウス及びこれを用いた薬物スクリーニング方法 Download PDFInfo
- Publication number
- JP2013054023A JP2013054023A JP2011223127A JP2011223127A JP2013054023A JP 2013054023 A JP2013054023 A JP 2013054023A JP 2011223127 A JP2011223127 A JP 2011223127A JP 2011223127 A JP2011223127 A JP 2011223127A JP 2013054023 A JP2013054023 A JP 2013054023A
- Authority
- JP
- Japan
- Prior art keywords
- git1
- test
- hyperactivity
- protein
- mouse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 238000012216 screening Methods 0.000 title claims abstract description 16
- 101150002882 git1 gene Proteins 0.000 title claims description 16
- 238000011813 knockout mouse model Methods 0.000 title abstract 3
- 102100039601 ARF GTPase-activating protein GIT1 Human genes 0.000 claims abstract description 69
- 101000888659 Homo sapiens ARF GTPase-activating protein GIT1 Proteins 0.000 claims abstract description 69
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims abstract description 47
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 37
- 208000013403 hyperactivity Diseases 0.000 claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 239000000126 substance Substances 0.000 claims abstract description 19
- 210000004556 brain Anatomy 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 241000282414 Homo sapiens Species 0.000 claims abstract description 7
- 102000006575 G-Protein-Coupled Receptor Kinases Human genes 0.000 claims abstract description 5
- 108010008959 G-Protein-Coupled Receptor Kinases Proteins 0.000 claims abstract description 5
- 230000001537 neural effect Effects 0.000 claims abstract description 3
- 230000002950 deficient Effects 0.000 claims description 52
- 238000012360 testing method Methods 0.000 claims description 34
- 241001465754 Metazoa Species 0.000 claims description 15
- 230000000694 effects Effects 0.000 claims description 12
- 230000006735 deficit Effects 0.000 claims description 11
- 229940124597 therapeutic agent Drugs 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 238000012347 Morris Water Maze Methods 0.000 claims description 8
- 230000003542 behavioural effect Effects 0.000 claims description 8
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 6
- 238000012346 open field test Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 3
- 230000000069 prophylactic effect Effects 0.000 claims description 3
- 230000000946 synaptic effect Effects 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 2
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 239000000419 plant extract Substances 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract description 43
- 230000007812 deficiency Effects 0.000 abstract description 10
- 238000011084 recovery Methods 0.000 abstract description 9
- 241000124008 Mammalia Species 0.000 abstract description 8
- 210000001652 frontal lobe Anatomy 0.000 abstract description 8
- 238000004458 analytical method Methods 0.000 abstract description 7
- 210000000225 synapse Anatomy 0.000 abstract description 5
- 230000001939 inductive effect Effects 0.000 abstract description 2
- 230000002549 cytobiological effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 53
- 241000699666 Mus <mouse, genus> Species 0.000 description 46
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 18
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 11
- 229960003638 dopamine Drugs 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 229940025084 amphetamine Drugs 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 230000006399 behavior Effects 0.000 description 9
- 230000013016 learning Effects 0.000 description 8
- 238000011160 research Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 230000007246 mechanism Effects 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 239000006180 TBST buffer Substances 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 210000005013 brain tissue Anatomy 0.000 description 5
- 230000007087 memory ability Effects 0.000 description 5
- 210000002569 neuron Anatomy 0.000 description 5
- 208000020016 psychiatric disease Diseases 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000003595 spectral effect Effects 0.000 description 5
- 201000003101 Coloboma Diseases 0.000 description 4
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 108010032428 Protein Deglycase DJ-1 Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000003520 dendritic spine Anatomy 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- 230000015654 memory Effects 0.000 description 4
- 229960001344 methylphenidate Drugs 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- 208000011117 substance-related disease Diseases 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 102000003678 AMPA Receptors Human genes 0.000 description 3
- 108090000078 AMPA Receptors Proteins 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000209094 Oryza Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000007659 Protein Deglycase DJ-1 Human genes 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 229940126585 therapeutic drug Drugs 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- UUDAMDVQRQNNHZ-UHFFFAOYSA-N (S)-AMPA Chemical compound CC=1ONC(=O)C=1CC(N)C(O)=O UUDAMDVQRQNNHZ-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- -1 PLCγ Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 2
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 2
- 108091005764 adaptor proteins Proteins 0.000 description 2
- 102000035181 adaptor proteins Human genes 0.000 description 2
- 230000036506 anxiety Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000010877 cognitive disease Diseases 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 230000014511 neuron projection development Effects 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000008447 perception Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000000379 polymerizing effect Effects 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QYCKVZZMAXDBHQ-UHFFFAOYSA-N 1-piperidin-4-ylbenzimidazole Chemical class C1CNCCC1N1C2=CC=CC=C2N=C1 QYCKVZZMAXDBHQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 101710146526 Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 102000004384 Histamine H3 receptors Human genes 0.000 description 1
- 108090000981 Histamine H3 receptors Proteins 0.000 description 1
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 description 1
- 101000605835 Homo sapiens Serine/threonine-protein kinase PINK1, mitochondrial Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000011250 Liprin-alpha Human genes 0.000 description 1
- 108050001497 Liprin-alpha Proteins 0.000 description 1
- 229940124647 MEK inhibitor Drugs 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000018546 Paxillin Human genes 0.000 description 1
- ACNHBCIZLNNLRS-UHFFFAOYSA-N Paxilline 1 Natural products N1C2=CC=CC=C2C2=C1C1(C)C3(C)CCC4OC(C(C)(O)C)C(=O)C=C4C3(O)CCC1C2 ACNHBCIZLNNLRS-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 102100038376 Serine/threonine-protein kinase PINK1, mitochondrial Human genes 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108700031954 Tgfb1i1/Leupaxin/TGFB1I1 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000000561 anti-psychotic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 102000016966 beta-2 Adrenergic Receptors Human genes 0.000 description 1
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 125000004799 bromophenyl group Chemical group 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 210000004002 dopaminergic cell Anatomy 0.000 description 1
- 210000005064 dopaminergic neuron Anatomy 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 239000003395 histamine H3 receptor antagonist Substances 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000003446 memory effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000000422 nocturnal effect Effects 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 102000045222 parkin Human genes 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- ACNHBCIZLNNLRS-UBGQALKQSA-N paxilline Chemical compound N1C2=CC=CC=C2C2=C1[C@]1(C)[C@@]3(C)CC[C@@H]4O[C@H](C(C)(O)C)C(=O)C=C4[C@]3(O)CC[C@H]1C2 ACNHBCIZLNNLRS-UBGQALKQSA-N 0.000 description 1
- 229960000761 pemoline Drugs 0.000 description 1
- NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 108091006024 signal transducing proteins Proteins 0.000 description 1
- 102000034285 signal transducing proteins Human genes 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000020685 sleep-wake disease Diseases 0.000 description 1
- 102000030938 small GTPase Human genes 0.000 description 1
- 108060007624 small GTPase Proteins 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knockout animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
- A01K67/027—New breeds of vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0356—Animal model for processes and diseases of the central nervous system, e.g. stress, learning, schizophrenia, pain, epilepsy
Abstract
【解決手段】GIT1欠損マウスに対する分子生物学的、細胞生物学的、電気生物学的、動物行動学的分析に関し、候補物質である薬物投与により注意欠陥多動性障害である多動と前頭葉におけるシータ波の回復を観察し、注意欠陥多動性障害の回復を誘導することができる新たな薬物のスクリーニングを行う。
【選択図】図8
Description
本発明におけるGIT1欠損マウスの製作に使用された胚性幹細胞(ES cell、FHCRC−GT−S10−12C1)は、Fred Hutchinson Cancer Centerから購入した。ES cell(embryonic stem cell)を500λのβ−mercaptoethanol、1%(v/v)ペニシリン/ストレプトマイシン、15%(v/v)のFBS(牛胎児血清)を含む培養液(Dulbecco's Modified Eagle Medium、DMEM、Gibco)に培養した後、前記細胞をC57BL/6マウスの胚盤胞(Blastcyst)に注入(microinjection)した。注入された胚盤胞はICR代理母マウスの子宮に着床させてキメラマウスを製作した。前記キメラマウスはアグチ色の毛の発現と重合酵素連鎖反応(PCR)を用いて遺伝子型を確認した。前記キメラマウスは、C57BL/6種と129/SV/Jae種とそれぞれ交配して繁殖した。各種から得られた異型接合体(Heterozygote)マウス間の交配により出たマウスを用いて本発明の実験に用いた。
前記実施例1のGIT1遺伝子の欠損を確認するために大きく二つの実験方法を使用した。第一の方法は、重合酵素連鎖反応を用いる方法であって、GIT1遺伝子の特定部分を増幅することができるプライマーセットを用いて、GIT1遺伝子の欠損有無を確認することができた。また、GIT1欠損マウスと異型マウスのみに含まれている外来遺伝子であるβgeoを増幅することができるプライマーをともに使用して、各マウスの遺伝子型を正確に把握することができた。重合酵素連鎖反応に使用されたプライマーセットの塩基配列は下記表1のとおりである。
本発明のGIT1欠損マウスを用いて多動観察のために新たな環境でオープンフィールド試験(Open field test)を行った。前記GIT1欠損マウスと対照群である正常マウス(Wild type)は2ヶ月〜5ヶ月のマウスを準備した。前記オープンフィールドはマウスに露出したことのない40−40−40cm(横−縦−高さ)の白色のボックスを準備し、マウスをオープンフィールドの中央に配置した後、60分間の移動距離をビデオ撮影し、行動分析プログラムを用いて全体移動距離、平均移動速度、中央空間侵入の割合などの結果を分析した。前記オープンフィールドにおける行動分析のために、オープンフィールドにマウスを配置する直前に、注意欠陥多動性障害を予防するための薬物として使用されるアンフェタミン(4mg/kg/day、1回)とメチルフェニデート(2mg/kg/day、1回)を腹腔注射した後、直ちにオープンフィールド中央に配置した。前記のような実験結果は図3のaに示されたように、正常マウスに比べてGIT1欠損マウスの移動距離は大きく、アンフェタミンとメチルフェニデートを投与した結果、図3のbとcでGIT1欠損マウスの移動距離は正常マウスのように驚くほど回復することを観察することができた。しかし、正常マウスに前記のような二つの薬物を投与した場合、移動距離が大きいと観察されたことはアナログ応答であると認識された。
本発明のGIT1欠損マウスを用いて見慣れた空間における多動症状を観察するために、ホームケージ活動性試験(Homecage activity test)を行った。本発明の試験は20−35−17cm規格のホームケージに前記の配置されたマウスを行動測定室に24時間配置して、マウスが行動実験室に馴化(habituation)するようにした。その後、12時間の明るい周期と12時間の暗い周期の間のマウスの行動をビデオ撮影し、動物行動分析プログラムを用いて全体移動距離を分析した。その結果、図4に示されたように、マウスの夜行性のため昼間にはマウスの行動が減少して移動距離が非常に短く、正常マウスとGIT1欠損マウスの間の移動距離に差がなかったが、行動が活発になる夜の場合には、本発明のGIT1欠損マウスが、親しい空間で、正常マウスに比べてより多い距離を移動し、多動を示す特徴があることを確認した。
本発明のGIT1欠損マウスを用いてモリス水迷路試験(Morris water maze test)によるマウスの空間学習及び記憶能力を測定した。前記モリス水迷路は直径120cmの白色の水槽に、不透明の直径10cmの踏み段を準備したものであって、前記マウスは一日に2回、30分ごとに踏み段の位置を把握して憶えるための訓練機会を有し、訓練は5日間連続して行われた。前記訓練による学習効果は図5に示したように、aでは正常マウスがGIT1欠損マウスに比べてより速い時間内に隠された踏み段を見つける結果が確認され、GIT1欠損マウスの空間知覚学習及び記憶能力が問題があることを確認することができた。また、bとcは、6日目に踏み段が除去された水槽で1分間のプローブテスト(probe test)を行い、水槽の各四分面でマウスが消耗する時間の割合を観察した結果、GIT1欠損マウスが実際に踏み段のある四分面で正常マウスに比べて時間を少なく消耗し、踏み段の位置を正確に通過する回数を動物行動分析プログラムにより分析した結果、GIT1欠損マウスが正常マウスに比べて踏み段の位置を正確に通過する回数が減少することが確認できた。
本発明のGIT1欠損マウスを用いて物体に対する認識及び記憶能力を分析するための物体認識試験(Novel object recognition test)は、オープンフィールド試験で使用されたオープンフィールドボックスで行われた。前記物体認識試験はサンプル期間(Sample phase)と試験期間(Test phase)とで構成された。サンプル期間中のマウスはオープンフィールドボックスに位置した同一の二つの物体を10分間探索し、これをビデオ撮影して前記マウスが二つの物体を観察した時間を記録した。その結果、図6で確認したように、aでは正常マウスとGIT1欠損マウスが物体を探索する時間は統計的に差がないと示された。また、例えば、二つの同一の物体のうち一つをマウスに露出しなかった新たな物体に変更し、24時間後に試験期間を行った。前記試験期間には10分が与えられ、この時間の間マウスが二つの物体を観察した時間を測定した。この場合、マウスの鼻先が物体に接触したり、マウスが物体から2cm以内で物体に向けていることを観察と規定した。本実験の物体認識及び記憶能力の回復を観察するため、サンプル期間20分前に、本発明のマウスに4mg/kg/dayの量のアンフェタミンあるいは食塩水を腹腔注射してオープンフィールドボックスに配置した。本実験結果、図6のbからは、GIT1欠損マウスが正常マウスに比べて新たな物体を認識する能力が劣ることが確認され、このような物体認識能力はADHD治療薬物であるアンフェタミンによって回復することを図6のcから確認することができた。
本発明のGIT1欠損マウスを用いて前頭葉における非正常のシータ領域の波形及び電力スペクトル密度(Power Spectrum Density)の分析のための実験は、ケタミン(ketamine)150mg/kgを腹腔注射して麻酔されたマウスの頭を定位固定(stereotaxic)して行った。EEG電極(electrode)は右側前頭葉と左側前頭葉に挿入し、具体的な座標はブレグマ(Bregma)を基準に前方2.8mm、側面0.8mmであり、定位固定(stereotaxic)機器を用いて正確な座標を算定して位置を取る。接地電極(grounding electrode)は後頭葉位置に挿入した。前記マウスは電極挿入後、一週間の回復期を送り、脳波測定時にEEG chamber内に挿入して1時間測定した。EEG信号はGrass model 7H polygraph(Grass Technologies)を用いて増幅した後、DIGIDATA 1320A(Molecular Devices)を用いて2000Hzのサンプリング周波数(sampling frequency)にデジタル化した後、pClamp8.0プログラム(Axon Instruments)を用いてデータを得て分析した。その分析結果は図7に示したように、aはGIT1欠損マウスの非正常のシータ波の波形が前頭葉から現れたことを示すものであり、bはパワースペクトル密度を示すものである。特に、アンフェタミンを投与した後には、cに示されたように、GIT1欠損マウスの多動と損傷された記憶力は、食塩水を投与した群より、非正常のシータ波の波形が回復することが分かった。
Claims (6)
- 脳の神経シナプスタンパク質であるGIT1(G protein−coupled receptor kinase interacting protein 1)遺伝子を欠損した非ヒト哺乳類を注意欠陥多動性障害モデルとして使用する方法。
- 1)GIT1遺伝子を欠損した非ヒト哺乳類に、注意欠陥または多動の予防剤または治療剤の候補物質を投与する段階と、
2)前記段階1)の候補物質を投与した後、前記非ヒト哺乳類の注意欠陥または多動テストを行う段階と、
3)前記候補物質を投与していない対照群と比較して注意欠陥または多動が減少した候補物質を選別する段階と、
を含む注意欠陥または多動の予防剤または治療剤のスクリーニング方法。 - 段階1)の非ヒト哺乳類は、マウス、ラット、豚または猿であることを特徴とする請求項2に記載の方法。
- 段階2)の注意欠陥または多動テストは、注意欠陥、多動、散漫及び行動障害から選択される一つ以上を特徴とする疾患を有したGIT1遺伝子欠損マウスに行うことを特徴とする請求項2に記載の方法。
- 段階1)の候補物質は、ペプチド、タンパク質、非ペプチド性化合物、合成化合物、醗酵生成物、細胞抽出液、植物抽出液、動物組織抽出液または血漿であることを特徴とする請求項2に記載の方法。
- 段階3)のスクリーニング方法は、オープンフィールド試験(Open field test)、ホームケージ活動性試験(Homecage activity test)、モリス水迷路試験(Morris water maze test)、物体認識試験(Novel object recognition test)及び脳波図(Electroencephealogram)試験から選択される一つ以上であることを特徴とする請求項2に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2011-0089182 | 2011-09-02 | ||
KR1020110089182A KR101127756B1 (ko) | 2011-09-02 | 2011-09-02 | Git1 유전자 결손 마우스 및 이를 이용한 약물 스크리닝 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013054023A true JP2013054023A (ja) | 2013-03-21 |
JP5436511B2 JP5436511B2 (ja) | 2014-03-05 |
Family
ID=46142404
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2011223127A Active JP5436511B2 (ja) | 2011-09-02 | 2011-10-07 | Git1遺伝子欠損マウス及びこれを用いた薬物スクリーニング方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US8552253B2 (ja) |
JP (1) | JP5436511B2 (ja) |
KR (1) | KR101127756B1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2011323235B2 (en) * | 2010-11-05 | 2015-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Optogenetic control of reward-related behaviors |
CN103704173A (zh) * | 2013-12-12 | 2014-04-09 | 内蒙古医科大学 | 一种内啮齿动物分散贮存食物行为的测定方法 |
CN106359290A (zh) * | 2016-09-19 | 2017-02-01 | 江苏三源生物科技有限公司 | 一种发酵床养殖巴马香猪的方法 |
KR102168455B1 (ko) * | 2017-08-10 | 2020-10-21 | 단국대학교 천안캠퍼스 산학협력단 | Git1 헤테로 타입 동물모델을 이용한 adhd 치료 약물 스크리닝 방법 |
KR102188534B1 (ko) | 2017-08-31 | 2020-12-08 | 고려대학교 산학협력단 | 조현병 동물모델 및 이의 제조방법 |
WO2019045273A1 (ko) * | 2017-08-31 | 2019-03-07 | 고려대학교 산학협력단 | 조현병 동물모델 및 이의 제조방법 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040058326A1 (en) | 2001-07-27 | 2004-03-25 | Brooksbank Robert Alan | Identification and use of molecules implicated in pain |
NZ535763A (en) | 2002-04-18 | 2007-06-29 | Schering Corp | (1-4-piperidinyl) benzimidazole derivatives useful as histamine H3 antagonists |
-
2011
- 2011-09-02 KR KR1020110089182A patent/KR101127756B1/ko not_active IP Right Cessation
- 2011-10-07 JP JP2011223127A patent/JP5436511B2/ja active Active
-
2012
- 2012-04-13 US US13/446,789 patent/US8552253B2/en active Active
Non-Patent Citations (1)
Title |
---|
JPN6013038711; Lee et al.: 'Modeling hyperactivity: of mice and men' Nature Medicine Vol.17,No.5, 201105, P.541-542 * |
Also Published As
Publication number | Publication date |
---|---|
US20130061338A1 (en) | 2013-03-07 |
KR101127756B1 (ko) | 2012-03-23 |
US8552253B2 (en) | 2013-10-08 |
JP5436511B2 (ja) | 2014-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Niwa et al. | Muscarinic acetylcholine receptors Chrm1 and Chrm3 are essential for REM sleep | |
JP5436511B2 (ja) | Git1遺伝子欠損マウス及びこれを用いた薬物スクリーニング方法 | |
Valdmanis et al. | Recent advances in the genetics of amyotrophic lateral sclerosis | |
Yang et al. | Forebrain-specific ablation of phospholipase Cγ1 causes manic-like behavior | |
Tadenev et al. | Model validity for preclinical studies in precision medicine: precisely how precise do we need to be? | |
JP2008505615A (ja) | 神経変性疾患及びその早期診断のためのモデルとしての非ヒトトランスジェニック動物 | |
Ichinose et al. | Development of a highly potent analogue and a long-acting analogue of oxytocin for the treatment of social impairment-like behaviors | |
Hawkins et al. | Epilepsy and neurobehavioral abnormalities in mice with a dominant-negative KCNB1 pathogenic variant | |
Meng et al. | Neurexophilin4 is a selectively expressed α-neurexin ligand that modulates specific cerebellar synapses and motor functions | |
Liu et al. | A dystonia-like movement disorder with brain and spinal neuronal defects is caused by mutation of the mouse laminin β1 subunit, Lamb1 | |
Tian et al. | Dosage sensitivity intolerance of VIPR2 microduplication is disease causative to manifest schizophrenia-like phenotypes in a novel BAC transgenic mouse model | |
Zhang et al. | Transmembrane and ubiquitin-like domain containing 1 (Tmub1) regulates locomotor activity and wakefulness in mice and interacts with CAMLG | |
EP3121282A1 (en) | Novel samdori-2 gene and use thereof | |
CA3149107A1 (en) | Use of tpk as a target in alzheimer's disease | |
JP4613824B2 (ja) | トランスジェニック非ヒト哺乳動物 | |
Merour et al. | Transient regulation of focal adhesion via Tensin3 is required for nascent oligodendrocyte differentiation | |
JP4905901B2 (ja) | Cd38による自閉症の診断と治療 | |
Bagley et al. | Neuron Navigator 1 Regulates Learning, Memory, and the Response to Multiple Potentially Addictive Drugs | |
Han et al. | Progress in the molecular genetic research in autism spectrum disorders | |
Marshall et al. | Early onset motor defects and electrographic seizures in a mouse model of the most common mutation in EEF1A2 related neurodevelopmental disorder, E122K | |
Wang et al. | Deficiency of FRMD5 results in neurodevelopmental dysfunction and autistic-like behavior in mice | |
US20090119786A1 (en) | Model animal of schizophrenia | |
CN110564771B (zh) | 脑钙化病模型的制备方法 | |
Blazejewski | Dissecting Cellular Mechanisms of Neurite Formation in the Developing Cortex | |
Marshall et al. | Face-valid phenotypes in a mouse model of the most common mutation in EEF1A2-related neurodevelopmental disorder |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130726 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131105 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20131125 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131210 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5436511 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |